4//SEC Filing
Ruff Shamim 4
Accession 0000899243-23-019539
CIK 0001358762other
Filed
Sep 25, 8:00 PM ET
Accepted
Sep 26, 4:30 PM ET
Size
22.1 KB
Accession
0000899243-23-019539
Insider Transaction Report
Form 4
Ruff Shamim
Director
Transactions
- Disposition to Issuer
Class A common stock
2023-09-26−7,359→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2023-09-26−443→ 0 totalExercise: $34.76Exp: 2032-06-08→ Class A common stock (443 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-09-26−2,137→ 0 totalExercise: $93.61Exp: 2033-06-07→ Class A common stock (2,137 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-09-26−780→ 0 totalExercise: $146.01Exp: 2031-06-10→ Class A common stock (780 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-09-26−3,334→ 0 totalExercise: $92.20Exp: 2031-04-15→ Class A common stock (3,334 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-09-26−576→ 0 totalExercise: $93.61Exp: 2033-06-07→ Class A common stock (576 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-09-26−1,405→ 0 totalExercise: $34.76Exp: 2032-06-08→ Class A common stock (1,405 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-09-26−5,000→ 0 totalExercise: $146.01Exp: 2031-06-10→ Class A common stock (5,000 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)
- [F2](Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, withot uinterest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
Documents
Issuer
REATA PHARMACEUTICALS INC
CIK 0001358762
Entity typeother
Related Parties
1- filerCIK 0001685986
Filing Metadata
- Form type
- 4
- Filed
- Sep 25, 8:00 PM ET
- Accepted
- Sep 26, 4:30 PM ET
- Size
- 22.1 KB